Trademark Overview
On Monday, July 20, 2026, a trademark application was filed for NEXVOUND with the United States Patent and Trademark Office. The USPTO has given the NEXVOUND trademark a serial number of 50001623. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, July 20, 2026. This trademark is owned by Eli Lilly and Company. The NEXVOUND trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, infectious diseases, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, opioid use disorder, osteoarthritis, pain, Parkinson's disease, psoriasis, psoriatic arthritis, pulmonary diseases, retinal disease, rheumatoid arthr...
